, Tracking Stock Market Picks
Enter Symbol:
galena biopharma (GALE) [hlAlert]

down 3.87 %

galena biopharma (GALE) rated Overweight by Piper Jaffray

Posted on: Monday,  Dec 31, 2012  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight galena biopharma (NASDAQ: GALE) on 12/31/2012, when the stock price was $1.55. Since
then, galena biopharma has lost 3.87% as of 01/21/2016's recent price of $1.49.
If you would have followed this Piper Jaffray's recommendation on GALE, you would have lost 3.87% of your investment in 1116 days.

RXi Pharmaceuticals Corporation (RXi) is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid interference (RNAi) for the treatment of human diseases. The Company is focused on internal research and development programs on certain inflammatory and metabolic diseases, and to pursue other therapeutic areas with potential partners. RXi commenced operations after CytRx Corporation contributed to the Company its portfolio of RNAi therapeutic assets, which consisted primarily of RNAi licenses and related intellectual property, and a nominal amount of equipment. As of December 31, 2008, the Company had not generated any revenues.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/31/2012 8:25 AM Buy
as of 8/27/2015
1 Week down  -1.32 %
1 Month down  -23.19 %
3 Months up  9.55 %
1 YTD down  -69.95 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy